Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

Main Article Content

Mauro Passucci https://orcid.org/0000-0002-1872-2218
Francesca Fazio
Jacopo Micozzi
Manhaz Shafii Bafti
Giovanni Manfredi Assanto https://orcid.org/0000-0002-6190-9635
Alfonso Piciocchi https://orcid.org/0000-0001-8648-885X
Maurizio Martelli
Maria Teresa Petrucci https://orcid.org/0000-0003-0688-4882

Keywords

daratumumab, stem cell mobilization, transplant

Abstract

Not applicable.

Downloads

Download data is not yet available.


Abstract 662
PDF Downloads 135
Suppl. Files Downloads 84
HTML Downloads 9

References

1. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide,
Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. April
2017;376(14):1311–20.
2. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous
Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the
BMT CTN 0702 Trial. J Clin Oncol. March 2019;37(7):589–97.
3. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous
haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or
without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide
maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised,
open-label, phase 3 study. Lancet Haematol. June 2020;7(6):e456–68.
4. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al.
International myeloma working group (IMWG) consensus statement and guidelines regarding
the current status of stem cell collection and high-dose therapy for multiple myeloma and the
role of plerixafor (AMD 3100). Leukemia. October 2009;23(10):1904–12.
5. Sánchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, et al.
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low
circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow
Transplant. January 2015;50(1):34–9.
6. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide,
and dexamethasone with or without daratumumab before and after autologous stem-cell
transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-
label, phase 3 study. Lancet. July 2019;394(10192):29–38.
7. Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, et al. Stem cell yield and
transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving
daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica. August 2021;106(8):2257–60.
8. Eleutherakis Papaiakovou E, Terpos E, Kanellias N, Migkou M, Gavriatopoulou M, Ntanasis-
Stathopoulos I, et al. Impact of daratumumab on stem cell mobilization and collection,
engraftment and early post-transplant complications among multiple myeloma patients
undergoing autologous stem cell transplantation. Leukemia & Lymphoma. September
2023;0(0):1–8.
9. Wang Y, Li Y, Chai Y. Efficacy and safety of daratumumab in the treatment of multiple myeloma:
a systematic review and meta-analysis. J Int Med Res. August 2021;49(8):03000605211038135.